Phase ii study of a combination of irinotecan and cisplatin against metastatic gastric cancer

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 319-323

  Boku, Narikazu ^a   Ohtsu, Atsushi ^a   Shimada, Yasuhiro ^a   Shirao, Kuniaki ^a   Seki, Shigeki ^a   Saito, Hiroshi ^a   Sakata, Yuh ^a   Hyodo, Ichinosuke ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL TIME;

EID: 0032919992     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.319     Document Type: Article

References (29)

1. Lacave AJ, Izarzugaza I, Anton Aparicio LM, et al: Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 6:35-38, 1983
2. Moertel CG, Rubin J, O'Connel MJ, et al: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4:1053-1057, 1986
3. Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317, 1989
4. Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-fluorouracil (ECF). Ann Oncol 5:609-616, 1994
5. Ohtsu S, Shimada S, Yoshida S, et al: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A:2091-2093, 1994
6. Kim NK, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3918, 1993
7. Kelsen D, Atiq O, Saltz L, et al: FAMTX versus etoposide, adriamycin, cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10:541-548, 1991
8. Wilke H, Wils J, Rougier P, et al: Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer: A trial of the EORTC gastrointestinal tract cancer cooperative group and the AIO. Proc Am Soc Clin Oncol 14:206, 1995 (abstr)
9. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
10. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A 84:5565-5569, 1987
11. Hsing YH, Liu LF, Wall ME, et al: DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4835-4839, 1989
12. Matsuzaki T, Yokokura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988
13. Kambe M, Wakui A, Nakano I, et al: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 12:198, 1993 (abstr 584)
14. Fukada M, Nishio K, Kanzawa F, et al: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small-cell lung cancer cells. Cancer Res 56:789-793, 1996
15. Masuda N, Fukuoka A, Fujita A, et al: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Brit J Cancer 78:251-256, 1998
16. Nagao K, Kuriyama T, Niitani H, at al: A phase II study of Irinotecan (CPT-11) combined with cisplatin (CDDP) on non-small-cell lung cancer (NSCLC). 18th International Congress of Chemotherapy, Stockholm, Sweden. June 27-July 2, 1993 (abstr 1646)
17. Shirao K, Shimada Y, Kondoh H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997
18. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
19. Wils J, Bleiberg H, Dalesio O, et al: An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4:1799-1803, 1986
20. Wilke H, Preusser P, Fink U, et al: High dose folinic acid/ etoposide/5-fluorouracil in advanced gastric cancer: Phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8:65-70, 1990
21. Nagoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
22. Rothenberg ML, Kuhn JB, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
23. de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacological study of the camptothecin derivative irinotecan administration on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994
24. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
25. Abigerges D, Charbot G, Armand J, et al: Phase I and pharmacological study of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
26. Catimel G, Charbot GG, Gaustalla JP, et al: Phase I and pharmacologic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995
27. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1992
28. Abigerges D, Armand JP, Charbot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:464-469, 1994
29. Armand JP: CPT-11: Clinical experience in phase I studies. Semin Oncol 23:27-33, 1996